TABLE 5.

Summary of nonhuman primate SIV immunization regimens^a

Trial	Immunogen	Challenge	Route	Treatment				No. of nonhuman primates with:
				Prime	Boost 1	Boost 2	Boost 3	Breakthrough	Protection	Total
M15	SIVmac239	SIVsmE660	Vaginal	DNA	DNA	MVA	MVA	5	4	9
M15	SIVmac239	SIVsmE660	Vaginal	DNA + GM-CSF	DNA + GM-CSF	MVA	MVA	7	3	10
M2	SIVmac239	SIVsmE660	Vaginal	VLP + alum	VLP + alum	VLP + alum	VLP + alum	6	2	8
M2	SIVmac239	SIVsmE660	Vaginal	VLP + NP	VLP + NP	VLP + NP	VLP + NP	4	5	9
M2	SIVmac239	SIVsmE660	Vaginal	Protein + alum	Protein + alum	Protein + alum	Protein + alum	7	3	10
M2	SIVmac239	SIVsmE660	Vaginal	Protein + NP	Protein + NP	Protein + NP	Protein + NP	5	5	10
M11	SIVmac239	SIVsmE660	Rectal	DNA	DNA	MVA	MVA	6	2	8
M11	SIVmac239	SIVsmE660	Rectal	MVA	MVA	MVA		6	2	8
M11	SIVmac239	SIVsmE660	Rectal	DNA + GM-CSF	DNA + GM-CSF	MVA	MVA	2	5	7
M12	SIVmac239	SIVsmE660	Rectal	DNA + CD40L	DNA + CD40L	MVA	MVA	8	4	12
Total								56	35	91

^aDNA, expresses SIVmac239 Gag, PR, Env, Tat, and Rev; MVA, modified vaccinia virus Ankara vector expressing SIVmac239 Gag, Pol, and Env with a truncated gp41; GM-CSF, granulocyte-macrophage colony-stimulating factor adjuvant expressed by a DNA plasmid; VLP, virus-like particles containing SIVmac230 Gag p55 and Env gp160; protein, SIVmac239 Env gp140 plus SIVmac239 Gag p55; NP, poly(lactic-coglycolic acid) nanoparticles with monophosphoryl lipid A and resiquimod (R848); CD40L, CD40 ligand adjuvant expressed by a DNA plasmid.